Hemagen Diagnostics (Hemagen Diagnostics) EBIT per Share : $-0.03 (TTM As of Sep. 2012)

View and export this data going back to . Start your Free Trial

What is Hemagen Diagnostics EBIT per Share?

Hemagen Diagnostics's EBIT per Share for the three months ended in Sep. 2012 was $-0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2012 was $-0.03.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Hemagen Diagnostics's EBIT per Share or its related term are showing as below:

HMGN's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.4
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Hemagen Diagnostics's EBIT for the three months ended in Sep. 2012 was $-0.04 Mil.

Hemagen Diagnostics EBIT per Share Historical Data

The historical data trend for Hemagen Diagnostics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hemagen Diagnostics EBIT per Share Chart

Hemagen Diagnostics Annual Data

Trend

Sep03

Sep04

Sep05

Sep06

Sep07

Sep08

Sep09

Sep10

Sep11

Sep12

EBIT per Share

Get a 7-Day Free Trial

0.01

-0.02

0.02

-0.03

Hemagen Diagnostics Quarterly Data
	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12
EBIT per Share	Get a 7-Day Free Trial															-0.01	-0.02	-0.01	-	-

Hemagen Diagnostics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Hemagen Diagnostics's EBIT per Share for the fiscal year that ended in Sep. 2012 is calculated as

	EBIT per Share		(A: Sep. 2012 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.438	/	15.496
=	-0.03

Hemagen Diagnostics's EBIT per Share for the quarter that ended in Sep. 2012 is calculated as

	EBIT per Share		(Q: Sep. 2012 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.043	/	15.500
=	-0.00

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2012 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.03

Hemagen Diagnostics (OTCPK:HMGN) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Hemagen Diagnostics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Hemagen Diagnostics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Hemagen Diagnostics (Hemagen Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemagen Diagnostics Inc (OTCPK:HMGN) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

9033 Red Branch Road, Columbia, MD, USA, 21045

Website

http://www.hemagen.com

Hemagen Diagnostics Inc is a biotechnology company. It develops, manufactures and markets Food and Drug Administration cleared proprietary medical diagnostic test kits and components. The company's Virgo line of Immunoassays are used to aid in the diagnosis of autoimmune and infectious diseases and acute-phase proteins. The assays utilize multiple technologies including ELISA, immunofluorescence (IFA) and hemagglutination (HA). Its products include ANA Screen ELISA 96 Test System, Rubella IgG ELISA 96 Test System, AMA IFA 48 Test System and others.

Executives

Howard F Curd

director

Hemagen Diagnostics (Hemagen Diagnostics) Headlines

No Headlines